Ovarian Function Following Intraovarian Injection of PRP

Description

Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).

Conditions

Diminished Ovarian Reserve, Diminished Ovarian Reserve Due to Advanced Maternal Age

Talk to us

Study Overview

On this page

Study Details

Study overview

Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).

Randomized Controlled Trial of Ovarian Function Following Intraovarian Injection of Platelet Rich Plasma for Women With Ovarian Aging

Ovarian Function Following Intraovarian Injection of PRP

Condition
Diminished Ovarian Reserve
Intervention / Treatment

-

Contacts and Locations

New York

Center for Human Reproduction, New York, New York, United States, 10021

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * fewer than 6 oocytes in response to past ovulation induction
  • * desire to establish a pregnancy using IVF
  • * Age 44 years and under.
  • * FSH \> 12
  • * AMH \< 1.0
  • * No Aspirin or Motrin for one week before treatment
  • * Age \> 45 years
  • * Marked thrombocytopenia
  • * Blood diseases
  • * Hypofibrinogenemia
  • * Hemodynamic instability
  • * Anticoagulant or antiaggregant treatment
  • * Oncological diseases (specially, skeletal system and blood)
  • * Sepsis
  • * Acute and chronic infectious diseases
  • * Autoimmune diseases, for example, lupus erythematosus, etc.

Ages Eligible for Study

21 Years to 44 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Center for Human Reproduction,

David H Barad, MD, PRINCIPAL_INVESTIGATOR, Center for Human Reproduction

Study Record Dates

2026-06-30